A Phase 4 interventional study of Salmeterol/Fluticasone 50/250 mcg and Salbutamol 100 mcg in Asthma, sponsored by GlaxoSmithKline. Completed at 32 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-09.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies testing albuterol in Asthma — 8 open to participants now, 9 under way, 1 of them phase 3. Albuterol · Asthma.
Among the 72 studies testing albuterol in Asthma, this one is the 13th largest by enrollment, is one of 4 that started in 2006, is one of 25 in phase 4, and was the 5th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →8 of the 72 studies testing albuterol in Asthma are open now, in 6 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of British Columbia · Sites in Canada
Ages 18–55 · Healthy volunteers
GlaxoSmithKline · Sites in United Kingdom
Ages 18–65
Hat Yai Medical Education Center · Sites in Thailand
Ages 18–60
By country, each count listing its studies:
Albuterol: first FDA approval 1981 (PROVENTIL). What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 4 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 221 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 63 across the 72 interventional studies. Of the 53 that completed or were terminated, 27 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 72 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 91st largest by enrollment of the 238 interventional ones that give a count, is one of 11 that started in 2006, is one of 53 in phase 4, and was the 25th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
2 of the studies testing albuterol in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06433921GlaxoSmithKlineA Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive | 2027-04-16 |
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 72 studies testing albuterol in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
The majority of asthma patients are not well controlled, despite the availability of asthma medication that could effectively treat the disease. In this study uncontrolled patients who are steroid-naive or on low dose inhaled corticosteroids will be treated with Seretide (salmeterol/fluticasone combination, SFC) 50/250 µg twice daily. The asthma control test (ACT) will be used to detect differences in the level of asthma control during treatment. The study aims to show a correlation between improvements of ACT und the level of asthma control which will be reached by the patients.
The aim of the study is to show that most of symptomatic asthma patients can reach 'well controlled asthma' with SFC. We get information about ACT in daily practice and physicians are trained to use the asthma control test as a screening tool and for follow up of asthma management. Correlations are expected between the improvements in ACT, Quality of Life and asthma control according to the Gaining Optimal Asthma controL (GOAL) criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received the combination product, fluticasone 250 microgram (mcg) plus salmeterol 50 mcg (SFC 50/250 mcg) for 12 weeks. Study treatment was received using DISKUS™ powder inhalers, one dose in morning and evening. Study medication was dispensed at visits 3, 4, and 5 for 30 days each. The participants were provided with salbutamol rescue medication if they developed acute asthmatic symptoms. This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. Use of rescue medications was recorded in the participant's asthma diaries. Stable dosages of other concomitant medications were allowed if they had no impact on the outcome criteria.
Drug: Salmeterol/Fluticasone 50/250 mcg · Drug: Salbutamol 100 mcg · Device: DISKUS™ powder inhalers
Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.
This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.
Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.
Percentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control Test (ACT) Score of 20-25 for Week 9 to Week 12
A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score \>1 (Range: 0= None to 5= severe), rescue salbutamol use on \<= 2 days and at most 4 occasions per week, and a morning peak flow \>= 80% of the predicted value on each day per week. All of the criteria which includes no night-time awakenings due to asthma (diary entry), no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change are fulfilled. The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control.
Time frame: Week 9 to Week 12
Change From Baseline in Percentage of Participants With ACT Score of 20-25 at Week 12
The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control. In order to derive the total ACT score, all 5 questions needed to be answered. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
Time frame: Baseline (Visit 3) and Week 12
Change From Baseline in Mean ACT Score at Visit 6
The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms not under control. In order to derive the total ACT score, all 5 questions had to be answered. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
Time frame: Baseline (Viait 3) and Week 12
Number of Participants With Well Controlled and Totally Controlled Asthma at Week 12
Well controlled or totally controlled asthma assessments were done according to the GOAL criteria. A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score \>1(Range: 0= None to 5= severe), rescue salbutamol use on \<= 2 days and at most 4 occasions per week, and morning peak flow \>= 80% of the predicted value on each day per week. All of the criteria which included no night-time awakenings due to asthma (diary entry),no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change were fulfilled. The total ACT score was based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
Time frame: Week 12
Change From Baseline in Quality of Life Using the Asthma Quality of Life Questionnaire (AQLQ)
For the level of asthma control, baseline values were derived taking the last 8 weeks during the pre-treatment period prior to Visit 3 into consideration. Regarding derived variables based on the asthma diary, data from the last week prior to Visit 3 was taken. Visit 3, regarded as baseline. AQLQ has 32 questions regarding activities, emotions, symptoms, and environmental triggers. Each item values range from 1 (maximum impairment) to 7 (no impairment). A positive change from baseline score indicates improvement.
Time frame: Baseline (Visit 3) up to Week 12
Correlation of Change in AQLQ Score and Change in ACT Score
Correlation between change in the AQLQ and ACT score was tabulated using the Pearson coefficient of correlation (linear correlation). The AQLQ contained 32 items in 4 domains: activity limitation, symptoms, emotional function and environmental stimuli. Scores for the domains as well as the overall score were scaled within a range of 1 (worst) to 7 (best).
Time frame: Week 12
Change From Baseline in Forced Expiratory Volume (FEV1) to Week 12
FEV1, an amount of air exhaled by a person during a forced breath in one second. FEV1 assessed at Visit 1 and at Visits 3, 4, 5, 6. Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.
Time frame: Baseline (Visit 3) up to Week 12
Change From Baseline in Mean Morning Percent Predicted Peak Expiratory Flow (PEF) at Week 12
PEF, a person's maximum speed of expiration, as measured with a peak flow meter, a small, hand-held device used to monitor a person's ability to breathe out air. The mean morning PEF evaluated by means of the data documented in the asthma diaries. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
Time frame: Baseline (Visit 3) and Week 12
Change From Baseline in Mean 24-hour Symptom Score at Week 12
The various symptoms like wheezing, shortness of breath, coughing and chest tightness were assessed by the participants every morning using a symptom score scale which ranged from 0 (no symptoms during the past 24 hours) to 5 (symptoms so severe that participant could not go to work or carry out other normal daily activities). Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
Time frame: Baseline (Visit 3) and Week 12
Change From Baseline in Number of Additional Usage of Salbutamol at Week 12
Salbutamol was given as a rescue medicine, used on \<= 2 days and at most 4 occasions per week. Change from baseline value was calculated by subtracting the baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
Time frame: Baseline (Visit 3) and week 12
Percent Change From Baseline in Number of Nights With no Nocturnal Awakening at Week 12
Number of nights with no night time awakening were recorded at Week 12. Baseline was the last corresponding time period immediately prior to Visit 3.
Time frame: Baseline (Visit 3) and week 12
Number of Participants With Emergency Visits Due to Asthma
Frequencies of emergency visits per participant were recorded during treatment period. Only the participants at risk were considered when calculating the incidence rates.
Time frame: Up to week 12
Number of Participants With Adverse Events (AE) Leading to a Change in Asthma Treatment
AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. Number of participants with AE who lead to change in asthma treatment were reported.
Time frame: Up to Week 12
Assessment of Tolerability by Number of Participants With at Least One Treatment Emergent Serious and, Non-serious AE
An AE is any untoward medical occurrence in a participant or clinical AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. Number of participants with at least one treatment emergent serious and, non-serious AE were reported.
Time frame: Up to Week 12
Assessment of Tolerability by Change From Baseline of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SBP and DBP were recorded over time (Visit 1, 3, 4, 5, and 6). Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.
Time frame: Baseline (Visit 3) up to Week 12
Assessment of Tolerability by Change From Baseline of Pulse Rate
Pulse rate was recorded over time (Visit 1, 3, 4, 5, and 6). Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.
Time frame: Baseline (Visit 3) up to Week 12
Number of Participants With Occurrence of (Near-) Incidents Associated With Peak Flow Measurements
Frequencies of participants with at least one (near-) incident associated with peak flow measurements were recorded. analysis was done on safety population.
Time frame: Up to Week 12
Study was conducted at 27 centers in Germany from 17 May 2006 to 6 September 2007 on participants diagnosed with perennial bronchial asthma.
| Milestone | SFC 50/250 mcg |
|---|---|
| Started | 221 |
| Completed | 204 |
| Not completed | 17 |
| Withdrew: Criteria for treatment period not fulfil | 1 |
| Withdrew: Adverse event | 4 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Non-compliance of subject | 1 |
| Withdrew: Participant discontinued on its own | 1 |
A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score \>1 (Range: 0= None to 5= severe), rescue salbutamol use on \<= 2 days and at most 4 occasions per week, and a morning peak flow \>= 80% of the predicted value on each day per week. All of the criteria which includes no night-time awakenings due to asthma (diary entry), no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change are fulfilled. The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control.
| Percentage | SFC 50/250 mcg |
|---|---|
| GOAL | 33.5 |
| ACT | 64.1 |
The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control. In order to derive the total ACT score, all 5 questions needed to be answered. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
| Participants | SFC 50/250 mcg |
|---|---|
| Baseline | 32 |
| Week 12 | 139 |
The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms not under control. In order to derive the total ACT score, all 5 questions had to be answered. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
| Score on a scale | SFC 50/250 mcg |
|---|---|
| Change From Baseline in Mean ACT Score at Visit 6 | 5.0 ± 4.3 |
Well controlled or totally controlled asthma assessments were done according to the GOAL criteria. A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score \>1(Range: 0= None to 5= severe), rescue salbutamol use on \<= 2 days and at most 4 occasions per week, and morning peak flow \>= 80% of the predicted value on each day per week. All of the criteria which included no night-time awakenings due to asthma (diary entry),no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change were fulfilled. The total ACT score was based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
| Participants | SFC 50/250 mcg |
|---|---|
| Well Controlled | 65 (23 to 36) |
| Totally Controlled | 29 |
For the level of asthma control, baseline values were derived taking the last 8 weeks during the pre-treatment period prior to Visit 3 into consideration. Regarding derived variables based on the asthma diary, data from the last week prior to Visit 3 was taken. Visit 3, regarded as baseline. AQLQ has 32 questions regarding activities, emotions, symptoms, and environmental triggers. Each item values range from 1 (maximum impairment) to 7 (no impairment). A positive change from baseline score indicates improvement.
| Score on Scale | SFC 50/250 mcg |
|---|---|
| Change From Baseline in Quality of Life Using the Asthma Quality of Life Questionnaire (AQLQ) | 0.83 ± 0.91 |
Correlation between change in the AQLQ and ACT score was tabulated using the Pearson coefficient of correlation (linear correlation). The AQLQ contained 32 items in 4 domains: activity limitation, symptoms, emotional function and environmental stimuli. Scores for the domains as well as the overall score were scaled within a range of 1 (worst) to 7 (best).
| participants | SFC 50/250 mcg |
|---|---|
| Correlation of Change in AQLQ Score and Change in ACT Score | 0.522 |
FEV1, an amount of air exhaled by a person during a forced breath in one second. FEV1 assessed at Visit 1 and at Visits 3, 4, 5, 6. Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.
| Litre/second (L/Sec) | SFC 50/250 mcg |
|---|---|
| Week 4 | 0.133 ± 0.320 |
| Week 8 | 0.212 ± 0.359 |
| Week 12 | 0.181 ± 0.372 |
PEF, a person's maximum speed of expiration, as measured with a peak flow meter, a small, hand-held device used to monitor a person's ability to breathe out air. The mean morning PEF evaluated by means of the data documented in the asthma diaries. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
| Percentage | SFC 50/250 mcg |
|---|---|
| Change From Baseline in Mean Morning Percent Predicted Peak Expiratory Flow (PEF) at Week 12 | 7.798 ± 10.302 |
The various symptoms like wheezing, shortness of breath, coughing and chest tightness were assessed by the participants every morning using a symptom score scale which ranged from 0 (no symptoms during the past 24 hours) to 5 (symptoms so severe that participant could not go to work or carry out other normal daily activities). Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
| Score on Scale | SFC 50/250 mcg |
|---|---|
| Change From Baseline in Mean 24-hour Symptom Score at Week 12 | -0.590 ± 0.948 |
Salbutamol was given as a rescue medicine, used on \<= 2 days and at most 4 occasions per week. Change from baseline value was calculated by subtracting the baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
| Number of occassions | SFC 50/250 mcg |
|---|---|
| Change From Baseline in Number of Additional Usage of Salbutamol at Week 12 | -0.933 ± 1.331 |
Number of nights with no night time awakening were recorded at Week 12. Baseline was the last corresponding time period immediately prior to Visit 3.
| Percent Change | SFC 50/250 mcg |
|---|---|
| Percent Change From Baseline in Number of Nights With no Nocturnal Awakening at Week 12 | 7.228 ± 24.921 |
Frequencies of emergency visits per participant were recorded during treatment period. Only the participants at risk were considered when calculating the incidence rates.
| Participants | SFC 50/250 mcg |
|---|---|
| At least 1 day | 13 |
| 1 day | 10 |
| 2 days | 2 |
| 3-4 days | 1 |
| 5-9 days | 0 |
AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. Number of participants with AE who lead to change in asthma treatment were reported.
| Participants | SFC 50/250 mcg |
|---|---|
| Number of Participants With Adverse Events (AE) Leading to a Change in Asthma Treatment | 4 |
An AE is any untoward medical occurrence in a participant or clinical AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. Number of participants with at least one treatment emergent serious and, non-serious AE were reported.
| Participants | SFC 50/250 mcg |
|---|---|
| Any Non-Serious AE | 76 |
| Any Serious AE | 1 |
SBP and DBP were recorded over time (Visit 1, 3, 4, 5, and 6). Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.
| millimeters of mercury (mmHg) | SFC 50/250 mcg |
|---|---|
| SBP, Week 4 | 0.8 ± 12.7 |
| SBP, Week 8 | -0.7 ± 11.3 |
| SBP, Week 12 | 0.2 ± 13.5 |
| DBP, Week 4 | 0.2 ± 8.8 |
| DBP, Week 8 | -0.2 ± 8.4 |
| DBP, Week 12 | 0.6 ± 9.0 |
Pulse rate was recorded over time (Visit 1, 3, 4, 5, and 6). Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.
| Beats per minute (bpm) | SFC 50/250 mcg |
|---|---|
| Week 4 | 1.0 ± 9.0 |
| Week 8 | -0.2 ± 9.1 |
| Week 12 | 0.6 ± 10.2 |
Frequencies of participants with at least one (near-) incident associated with peak flow measurements were recorded. analysis was done on safety population.
| participants | SFC 50/250 mcg |
|---|---|
| Number of Participants With Occurrence of (Near-) Incidents Associated With Peak Flow Measurements | 0 |
Collected over Up to Week 12. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SFC 50/250 mcg | 1/221 (0.5%) | 1/221 (0.5%) | 76/221 (34.4%) |
| Event | SFC 50/250 mcg |
|---|---|
| Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/221 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/221 |
| Event | SFC 50/250 mcg |
|---|---|
| HeadacheNervous system disorders | 23/221 |
| NasopharyngitisInfections and infestations | 18/221 |
| BronchitisInfections and infestations | 12/221 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 8/221 |
| Respiratory tract infectionInfections and infestations | 6/221 |
| SinusitisInfections and infestations | 6/221 |
| Back painMusculoskeletal and connective tissue disorders | 5/221 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 4/221 |
| ToothacheGastrointestinal disorders | 3/221 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/221 |
| Age, Continuous(Years) | SFC 50/250 mcg |
|---|---|
| Mean | 49.5 ± 15.5 |
| Sex: Female, Male(Participants) | SFC 50/250 mcg |
|---|---|
| Female | 142 |
| Male | 79 |
Ran from May 2006 to primary completion in Sep 2007, 15 months.
Results were first posted in Mar 2018, 10 years 6 months after primary completion.
Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 15 months is below that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albuterol